Skip to main content
Download PDF

Hepatoid adenocarcinoma in ureter with next-generation sequencing: A case report and literature review

BMC Medical Genomics volume 17, Article number: 7 (2024) Cite this article

Abstract

Background

Hepatoid adenocarcinoma (HAC) is rare in the urinary system, with only 7 reported cases in upper urinary tract. This report aimed to explore the genetic characteristics of ureteral HAC for first time, and to describe the treatment prognosis of ureteral HAC.

Case presentation

We present a rare case of ureteral HAC in a 53-year-old female, showing elevated serum levels of AFP and CEA, prolonged chronic irritation may be an important cause of her ureteral HAC. Radical nephroureterectomy was performed, the serum levels of AFP and CEA decreased significantly, and metastasis in lymph nodes was found at 9 months after surgery, she had no related symptoms after 18 months postoperatively without adjuvant chemotherapy. Three driver somatic mutations in cancer were identified by NGS testing, including: TP53D281H, KMT2DL1211Ifs*2, KMT2DT1843Nfs*5, demonstrating that ureteral HAC has the similar mutational features to upper tract urothelial carcinoma. Homologous-recombination deficiency (HRD) was positive in this tumor with no mutations in HRD-related genes, which was possibly induced by the copy number deletion of SETD2 gene.

Conclusions

We report a rare case of ureteral HAC with elevated serum levels of AFP and CEA. NGS testing demonstrated that ureteral HAC has the similar mutational features to upper tract urothelial carcinoma, which is an important guide for the diagnosis and treatment of ureteral HAC.

Peer Review reports

Background

Hepatoid adenocarcinoma (HAC) is a rare type of extrahepatic adenocarcinoma with production of alpha-fetoprotein (AFP), which has a morphological phenotype of hepatocellular carcinoma (HCC) [1]. In 1985, HAC was first described in a case of gastric adenocarcinoma by Ishikura et al. [2] Like the typical HCC, immunohistochemical (IHC) staining of HAC usually showed positive AFP stains (91.6%), together with elevated serum levels of AFP in most cases but not in all [1, 3]. Meanwhile, positive carcinoembryonic antigen (CEA) stains were also found in most HAC patients (78.7%) [1]. Until now, HAC has been reported in several organs, and the stomach is the most common location of HAC in the literature [1, 4].

HAC was rarely reported in the urothelium, as far as we know, only 17 previous HAC cases in the urothelium were reported in the literature, including 10 cases of bladder [4, 5], 7 cases of renal pelvis and ureter [6]. In the current report, we present a case of HAC located in the ureter with production of AFP and CEA. Moreover, next-generation sequencing was applied to explore its molecular characterization, this seems to be the first documentation to study the molecular characteristics of HAC in the urothelium.

Case presentation

Clinical findings

A 53-year-old Chinese female was admitted to our hospital for complaining of 2-weeks gross hematuria in May, 2021. Pulmonary CT (computed tomography) scan and computed tomography urography (CTU) scan (Fig. 1A) were applied, revealing multiple mass lesions with enhancement in the middle and lower left ureter, which are considered to be neoplastic lesions. In addition, CTU also showed a stone with a diameter of 2 cm in the right kidney, while there were no other primary or metastatic lesions, especially in the liver, lung and gut. Her history was significant for left ureteroscopic lithotripsy (URSL) and ureteral stent placement for left ureteral stone at another hospital in 2017. In the following years, she underwent multiple ureteral stent placements, due to the recurrent ureteral strictures. Moreover, in August 2018, she underwent total hysterectomy for cervical high-grade squamous intraepithelial lesions. She has a history of hepatitis B and has no history of smoking.

Fig. 1
figure 1

a CTU scan showed a stone in the right kidney (circle) and enhanced lesions in the middle and lower left ureter (arrow); b Cystoscopy revealed a solitary tumor on the left ureteral opening of the bladder; c Hematoxylin-eosin (HE) stain showed the transitional area between tumor and uroepithelium, and the tumor cells were distributed in a trabecular and glandular pattern. Tumor cells stained positively for AFP, CEA, SALL4 and Ki67

Full size image

As part of her clinical workup, the fluorescence in situ hybridization result of her urine specimen was positive. Furtherly, cystoscopy was applied, revealing a solitary tumor on the left ureteral opening of the bladder (Fig. 1B). And the glomerular filtration rate (GFR) measured by 99 m Tc-DTPA renal dynamic imaging showed severe impairment of the left GFR (left GFR = 6.64 ml/min, right GFR = 54.65 ml/min). Serum AFP was detected to be 568.9 ng/ml (normal range < 6.6 ng/ml), serum CEA was 20.0 ng/ml (normal range < 7.2 ng/ml) and cancer antigen 199 (CA-199) was 99.51 U/ml (normal range < 37 U/ml). And serological markers for hepatitis B viruses HBV were positive (HBsAg+, HBeAb+, HBcAb+).

Based on these findings, the patient was diagnosed as having a tumor in left ureter combined with severe hydronephrosis of the left kidney, therefore radical nephroureterectomy was performed in May, 2021, with pathologically confirmation of HAC. Meanwhile, she underwent right ureteral stent placement combined with secondary retrograde intrarenal surgery for right kidney stone.

Pathology and immunohistochemistry

Surgically removed specimens were fixed in 10% buffered formalin, hematoxylin-eosin (HE) stain showed a T3-stage tumor with invasion to the ureteral muscle layer. The tumor cells were distributed in a trabecular and glandular pattern with no conventional urothelial carcinoma, and the transitional area between tumor and uroepithelium was visible (Fig. 1C). Adjuvant chemotherapy (Gemcitabine-cisplatin, GC) is recommended because the tumor is T3-stage, but the patient refused it.

As shown in Fig. 1C, IHC stains demonstrated that the cancer cells were positive for anti-AFP, anti-CEA, anti-SALL4 (spalt like transcription factor 4). Moreover, 60% of Ki67 positivity indicated a higher proliferation rate in the tumor. Combining tumor morphology and IHC characteristics, the tumor was diagnosed as a HAC with ureteral origin after a multidisciplinary discussion [1, 7].

Sequencing analysis

To explore the genomic alterations of ureteral HAC, next-generation sequencing (NGS) was performed to detected the mutational signatures in 537 cancer-associated genes. The NGS tests were done by Beijing Genomics Institute (Beijing, China). Firstly, germline variants testing using blood specimen revealed three mutations of unknown clinical significance, including: BRCA1N909I, IRS1G596R and ALKR672S, and the detailed mutation information is shown in Table 1. According to the data provided in the ClinVar databases (https://www.ncbi.nlm.nih.gov/clinvar/), BRCA1N909I is classified as likely benign, IRS1G596R have not been reported, while ALKR672S is classified as a variant of uncertain significance.

Table 1 Genomic alterations of ureteral HAC by NGS testing
Full size table

Furthermore, formalin-fixed paraffin-embedded (FFPE) tumor tissue was used to detected somatic variants. Except for the same germline variants as the blood specimen testing, three driver somatic mutations in cancer were identified, including: TP53D281H, KMT2DL1211Ifs*2, KMT2DT1843Nfs*5 (Table 1). TP53D281H is classified as a likely pathogenic mutation in ClinVar databases, which disrupts the p.Asp281 amino acid residue in TP53. While KMTD2 gene alteration is one of the most common mutations in upper tract urothelial carcinoma (UTUC) [8]. Additionally, the results of somatic copy number alterations testing showed copy number deletion of SETD2 gene and copy number amplification of AKT2 gene. And homologous-recombination deficiency (HRD) was positive in the tumor with an HRD score of 51 (HRD score of ≥42 on the myChoice HRD Plus assay), indicating that this patient may benefit from poly adenosine diphosphate–ribose polymerase inhibitors and platinum-containing therapy [9]. Moreover, the sequencing results revealed a low tumor mutational burden and microsatellite stability in this tumor, indicating a low sensitivity to programmed cell death-1 (PD-1) blockade for this patient [10].

Follow-up

As shown in Fig. 2, after 2 months postoperatively, the serum levels of AFP, CEA and CA-199 decreased significantly, the serum AFP level was 22.7 ng/ml, CEA 2.87 ng/ml, CA-199 9.14 U/ml. At about 9 months after surgery, the patient returned to the hospital for a follow-up examination, and serum AFP increased to 351.7 ng/ml, CEA 22.8 ng/ml. Moreover, as shown in Fig. 2D, metastasis in retroperitoneal lymph nodes and left common iliac lymph nodes was found on 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). GC chemical therapy was required, but the patient still refused it. After 18 months postoperatively, the patient had not come back for the second follow-up visit, and had no related symptoms when asked by telephone.

Fig. 2
figure 2

The follow-up of the serum levels of AFP a, CEA b and CA-199 c; d. 18F-FDG PET/CT scan showed metastasis in left common iliac lymph node after 9 months postoperatively

Full size image

Discussion and conclusions

HAC is a rare tumor with production of AFP, especially in the ureter and renal pelvis, a total of 8 cases of renal pelvis and ureter have been reported so far (Table 2). Except for case 3 whose AFP IHC information was not available, IHC staining were positive for AFP in all cases. Similarly, serum AFP levels increased in each case when available. Longstanding chronic inflammation and irritation due to calculi can induce primary adenocarcinoma in upper urinary tract [11,12,13]. Significantly, case 4 and two patients younger than 60 years (case 7 and our case) had the history of chronic irritation [6, 14]. Case 4 had an indwelling nephrostomy tube in the right kidney for many years, case 7 had the history of calculus in the right kidney, while our patient had undergone multiple ureteral stent placements for the recurrent ureteral strictures. Accordingly, we speculate that chronic irritation may be an important cause of ureteral and renal pelvic HAC, especially in the younger patients.

Table 2 Cases of ureteral and renal pelvic HAC in reviewed literatures
Full size table

All cases of ureteral and renal pelvic HAC in the literature were treated with radical nephroureterectomy, and serum AFP decreased to normal level in 86% (6/7) of patients within 1.5–5 months postoperatively (case 3 and case 5 are not available). Case 4 received radiotherapy because the metastasis in a retroperitoneal node was found after 9 months postoperatively, and the lymph node decreased in size by 80% after radiotherapy, demonstrating that ureteral and renal pelvic HAC is sensitive to radiotherapy [14]. None of the reported ureteral and renal pelvic HAC cases received chemotherapy, GC chemotherapy had been recommended to our patient for several times, but the patient refused it. The NGS testing of this patient proved the similar mutational features of ureteral HAC to UTUC, therefore, we conclude that GC chemotherapy is effective for ureteral and renal pelvic HAC, this need to be confirmed by further studies.

According to the case reports in the literature, the prognosis of HAC patients was poor in general, lymph nodes metastasis was found in 57.5% patients when HAC was diagnosed, and the median survival of all patients was 12 months [1]. However, the prognosis of HAC in the urothelium seems to be not very bad, which is manifested as no one died of the cancer within 1 year in the 4 cases followed for more than 12 months.

NGS testing was performed in this case to explore the genomic alterations of ureteral HAC, and BRCA1N909I mutation was found. BRCA1N909I is located in DNA binding domain of BRCA1, and classified as likely benign based on a multifactorial analysis [20]. Somatic variants detected by FFPE tumor tissue showed mutations in TP53 and KMT2D genes, demonstrating that ureteral HAC has the similar mutational features to UTUC [8]. Consistent with this, it was reported that gastric HAC had a similar mutation spectrum to gastric cancer but not HCC [21].

HRD results in impaired double strand break repair and is frequently observed in breast, ovarian and prostate cancers [22]. HRD was positive in this tumor with no mutations in HRD-related genes. However, the copy number deletion of SETD2 gene was observed, SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) was reported to be required in homologous recombination repair by promoting recruitment of RAD51 [23], the copy number deletion of SETD2 gene may be the reason for why the ureteral HAC show HRD-positive with no mutations in HRD-related genes.

In conclusion, we present a rare case of ureteral HAC showing elevated serum levels of AFP and CEA, prolonged chronic irritation may be the main cause of her ureteral HAC. NGS testing was applied to explore the genetic characteristics of ureteral HAC for first time, indicating the driver somatic mutations in TP53 and KMT2D genes, and HRD positivity possibly induced by the copy number deletion of SETD2 gene, which need to be confirmed by further studies. Our fndings could be helpful for the clinical diagnosis and treatment of ureteral HAC.

Availability of data and materials

The raw sequence data reported in this paper have been deposited in the Genome Sequence Archive in National Genomics Data Center, China National Center for Bioinformation / Beijing Institute of Genomics, Chinese Academy of Sciences (GSA-Human: HRA005075) that are publicly accessible at https://ngdc.cncb.ac.cn/gsa-human [24, 25].

Abbreviations

HAC:

Hepatoid adenocarcinoma

HRD:

Homologous-recombination deficiency

AFP:

alpha-fetoprotein

HCC:

hepatocellular carcinoma

IHC:

immunohistochemical

CEA:

carcinoembryonic antigen

CTU:

Computed tomography urography

URSL:

ureteroscopic lithotripsy

GFR:

glomerular filtration rate

CA-199:

cancer antigen 199

HE:

hematoxylin-eosin

GC:

Gemcitabine-cisplatin

SALL4:

spalt like transcription factor 4

NGS:

next-generation sequencing

FFPE:

formalin-fixed paraffin-embedded

UTUC:

upper tract urothelial carcinoma

PD-1:

programmed cell death-1

References

  1. Su JS, Chen YT, Wang RC, Wu CY, Lee SW, Lee TY. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review. World J Gastroenterol. 2013;19(3):321–7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ishikura H, Fukasawa Y, Ogasawara K, Natori T, Tsukada Y, Aizawa M. An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report Cancer. 1985;56(4):840–8.

    CAS  PubMed  Google Scholar 

  3. Lopez-Beltran A, Luque RJ, Quintero A, Requena MJ, Montironi R. Hepatoid adenocarcinoma of the urinary bladder. Virchows Arch. 2003;442(4):381–7.

    Article  CAS  PubMed  Google Scholar 

  4. Sekino Y, Mochizuki H, Kuniyasu H. A 49-year-old woman presenting with hepatoid adenocarcinoma of the urinary bladder: a case report. J Med Case Rep. 2013;7:12.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Friedman P, Lai JP. Liver metastasis of urothelial carcinoma with Hepatoid features: an unusual morphological finding. Anticancer Res. 2017;37(2):801–4.

    Article  PubMed  Google Scholar 

  6. Huang J, Zhu R, Wu R, Li R, Yao N, Deng S. Hepatoid adenocarcinoma of the renal pelvis in a 59-year-old male with nephrolithiasis: case report and review of the literature. Curr Probl Cancer. 2019;43(5):471–6.

    Article  PubMed  Google Scholar 

  7. Ushiku T, Shinozaki A, Shibahara J, Iwasaki Y, Tateishi Y, Funata N, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol. 2010;34(4):533–40.

    Article  PubMed  Google Scholar 

  8. Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE, et al. Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol. 2017;72(4):641–9.

    Article  CAS  PubMed  Google Scholar 

  9. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian Cancer. N Engl J Med. 2019;381(25):2416–28.

    Article  CAS  PubMed  Google Scholar 

  10. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Spires SE, Banks ER, Cibull ML, Munch L, Delworth M, Alexander NJ. Adenocarcinoma of renal pelvis. Arch Pathol Lab Med. 1993;117(11):1156–60.

    CAS  PubMed  Google Scholar 

  12. Kobayashi S, Ohmori M, Akaeda T, Ohmori H, Miyaji Y. Primary adenocarcinoma of the renal pelvis. Report of two cases and brief review of literature. Acta Pathol Jpn. 1983;33(3):589–97.

    CAS  PubMed  Google Scholar 

  13. Kalafatis P, Zarifis I, Sotrillis T, Stefis A. Mucinous adenocarcinoma of the renal pelvis associated with renal calculi of the inflammatory type. Minerva Urol Nefrol. 1999;51(1):45–8.

    CAS  PubMed  Google Scholar 

  14. Shiga Y, Kawai K, Shimazui T, Iijima T, Noguchi M, Akaza H. Case of alpha-fetoprotein-producing transitional cell carcinoma of the renal pelvis. Int J Urol. 2004;11(2):117–8.

    Article  PubMed  Google Scholar 

  15. Ishikura H, Ishiguro T, Enatsu C, Fujii H, Kakuta Y, Kanda M, et al. Hepatoid adenocarcinoma of the renal pelvis producing alpha-fetoprotein of hepatic type and bile pigment. Cancer. 1991;67(12):3051–6.

    Article  CAS  PubMed  Google Scholar 

  16. Hosomi M, Sagawa S, Kotou Y. Alpha-fetoprotein-producing adenocarcinoma of the ureter. Urol Int. 1992;48(2):226–7.

    Article  CAS  PubMed  Google Scholar 

  17. Aida Y, Kudo O, Yamakawa K, Kato K, Tadokoro M, Takahashi T. Papillary adenocarcinoma of the ureter producing carcinoembryonic antigen and carbohydrate antigen 19-9. J Urol. 2002;168(6):2535–6.

    Article  CAS  PubMed  Google Scholar 

  18. Rotellini M, Messerini L, Stomaci N, Raspollini MR. Hepatoid adenocarcinoma of the ureter: unusual case presenting hepatic and ovarian metastases. Appl Immunohistochem Mol Morphol. 2011;19(5):478–83.

    Article  CAS  PubMed  Google Scholar 

  19. Samaratunga H, Samaratunga D, Dunglison N, Perry-Keene J, Nicklin J, Delahunt B. Alpha-fetoprotein-producing carcinoma of the renal pelvis exhibiting hepatoid and urothelial differentiation. Anticancer Res. 2012;32(11):4987–91.

    PubMed  Google Scholar 

  20. Lee JS, Oh S, Park SK, Lee MH, Lee JW, Kim SW, et al. Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort. J Med Genet. 2018;55(12):794–802.

    Article  CAS  PubMed  Google Scholar 

  21. Liu Z, Wang A, Pu Y, Li Z, Xue R, Zhang C, et al. Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach. Oncogene. 2021;40(38):5705–17.

    Article  CAS  PubMed  Google Scholar 

  22. Nguyen L, WM Martens J, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11(1):5584.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Carvalho S, Vítor AC, Sridhara SC, Martins FB, Raposo AC, Desterro JM, et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife. 2014;3:e02482.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Chen T, Chen X, Zhang S, Zhu J, Tang B, Wang A, et al. The genome sequence archive family: toward explosive data growth and diverse data types. Genom Proteom Bioinform. 2021;19(4):578–83.

    Article  Google Scholar 

  25. CNCB-NGDC Members and Partners. Database resources of the National Genomics Data Center, China National Center for bioinformation in 2022. Nucleic Acids Res. 2022;50(D1):D27–38.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank the patient and his family members for taking part in this research.

Funding

This study was supported by National Natural Science Foundation of China (Grant No. 82103609).

Author information

Authors and Affiliations

  1. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China

    Mengxin Lu, Dongliang Hu, Jingtian Yu, Hang Zheng & Tongzu Liu

  2. Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China

    Yueying Li

Authors
  1. Mengxin Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yueying Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dongliang Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingtian Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hang Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tongzu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TZL conceived the idea and its design. MXL and JTY collected the data and drafted the manuscript. TZL, DLH, HZ and MXL administered the treatment for the patient. YYL, TZL and MXL made the pathological diagnosis. TZL and MXL reviewed and corrected the manuscript. All authors contributed to the article and approved the submitted version.

Corresponding author

Correspondence to Tongzu Liu.

Ethics declarations

Ethics approval and consent to participation

The studies involving human participants were reviewed and approved by Medical Ethics Committee, Zhongnan Hospital of Wuhan University (Ethical Approval No. 2020102). The patient provided her written informed consent to participate in this study. The study was carried out in accordance with the Helsinki Declaration.

Consent to publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, M., Li, Y., Hu, D. et al. Hepatoid adenocarcinoma in ureter with next-generation sequencing: A case report and literature review. BMC Med Genomics 17, 7 (2024). https://doi.org/10.1186/s12920-023-01776-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12920-023-01776-5

Keywords

BMC Medical Genomics

ISSN: 1755-8794

Contact us